Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: A meta-analysis

Internal Medicine Journal

Volumn 45, Issue 5, 2015, Pages 546-557

  Luo, L ^a   Yuan, X ^a   Huang, W ^a   Ren, F ^a   Zhu, H ^a   Zheng, Y ^a   Tang, L ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Adverse event; Ezetimibe; Hypercholesterolaemia; Meta analysis; Statin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT; LIPID;

ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); COMBINATION DRUG THERAPY; RISK FACTOR; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; DRUG THERAPY, COMBINATION; EZETIMIBE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPIDS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84928994108     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12706     Document Type: Article

References (34)

1. Sirtori CR. The pharmacology of statins. Pharmacol Res 2014; 88: 3-10.
2. Jeu L, Cheng JW. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin Ther 2003; 25: 2352-2387.
3. Stein EA. An investigative look: selective cholesterol absorption inhibitors - embarking on a new standard of care. Am J Manag Care 2002; 8: S36-39, discussion S45-37.
4. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
5. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R etal. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-2415.
6. Kerzner B, Corbelli J, Sharp S, Lipka LJ, Melani L, LeBeaut A etal. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003; 91: 418-424.
7. Melani L, Mills R, Hassman D, Lipetz R, Lipka L, LeBeaut A etal. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003; 24: 717-728.
8. Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R etal. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004; 26: 1758-1773.
9. Feldman T, Koren M, Insull W, McKenney J, Schrott H, Lewin A etal. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004; 93: 1481-1486.
10. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004; 79: 620-629.
11. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005; 149: 464-473.
12. Barrios V, Amabile N, Paganelli F, Chen JW, Allen C, Johnson-Levonas AO etal. Lipid-altering efficacy of switching from atorvastatin 10mg/day to ezetimibe/simvastatin 10/20mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J Clin Pract 2005; 59: 1377-1386.
13. Cruz-Fernandez JM, Bedarida GV, Adgey J, Allen C, Johnson-Levonas AO, Massaad R etal. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int J Clin Pract 2005; 59: 619-627.
14. Farnier M, Volpe M, Massaad R, Davies MJ, Allen C. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol 2005; 102: 327-332.
15. Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE etal. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006; 22: 2041-2053.
16. Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS etal. Efficacy and safety of ezetimibe added on to atorvastatin (20mg) versus uptitration of atorvastatin (to 40mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008; 102: 1489-1494.
17. Leiter LA, Bays H, Conard S, Bird S, Rubino J, Hanson ME etal. Efficacy and safety of ezetimibe added on to atorvastatin (40mg) compared with uptitration of atorvastatin (to 80mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008; 102: 1495-1501.
18. Zubaid M, Shakir DK, Bazargani N, Binbrek A, Gopal R, Al-Tamimi O etal. Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial. J Cardiovasc Med (Hagerstown) 2008; 9: 688-693.
19. Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R etal. Lipid-altering efficacy of ezetimibe/simvastatin 10/20mg compared with rosuvastatin 10mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract 2009; 63: 547-559.
20. Robinson JG, Ballantyne CM, Grundy SM, Hsueh WA, Parving HH, Rosen JB etal. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol 2009; 103: 1694-1702.
21. Averna M, Zaninelli A, Le Grazie C, Gensini GF. Ezetimibe/simvastatin 10/20mg versus simvastatin 40mg in coronary heart disease patients. J Clin Lipidol 2010; 4: 272-278.
22. Foody JM, Brown WV, Zieve F, Adewale AJ, Flaim D, Lowe RS etal. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults >/=65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). Am J Cardiol 2010; 106: 1255-1263.
23. Bays HE, Davidson MH, Massaad R, Flaim D, Lowe RS, Tershakovec AM etal. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol 2011; 108: 523-530.
24. Hing Ling PK, Civeira F, Dan AG, Hanson ME, Massaad R, De Tilleghem Cle B etal. Ezetimibe/simvastatin 10/40mg versus atorvastatin 40mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. Lipids Health Dis 2012; 11: 18-25.
25. LaRosa JC. Low-density lipoprotein cholesterol reduction: the end is more important than the means. Am J Cardiol 2007; 100: 240-242.
26. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G etal. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl 2004; 5: 81-87.
27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
28. Shepherd J. Preventing coronary artery disease in the West of Scotland: implications for primary prevention. Am J Cardiol 1998; 82: 57T-59T.
29. Morishita R, Tomita N, Ogihara T. HMG-Co A reductase inhibitors in the treatment of cardiovascular diseases: stabilization of coronary artery plaque. Curr Drug Targets 2002; 3: 379-385.
30. Tellier P. Ezetimibe: from pharmacology to clinical trials. Ann Endocrinol (Paris) 2003; 64: 442-447.
31. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003; 4: 779-790.
32. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M etal. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007; 29: 253-260.
33. Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 2006; 22: 511-528.
34. Davidson MH, Ballantyne CM, Kerzner B, Melani L, Sager PT, Lipka L etal. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004; 58: 746-755.